Undisclosed bi-functional antibody drug conjugate / TuHURA Bio - LARVOL DELTA

Currently Anticipated Milestones by Program: MDSC Inhibitors (Bi-specific ADCs) (PRNewswire)

Preclinical • Oncology

Upcoming Targeted Milestones by Program (PRNewswire) - "Lead ADC Selection: 1H 2026: Select lead ADC in AML; 2H 2026: Expect to initiate ADC in vivo proof of concept (POC) studies; 2H 2026: Anticipate POC data in humanized model of AML; 2H 2026: Presentations at key scientific meetings."

Pipeline update • Preclinical • Acute Myelogenous Leukemia

Upcoming Targeted Milestones by Program:…Lead ADC Selection (PRNewswire) - "(i) Q1 2026: TuHURA has developed a library of potent, highly selective DOR inhibitors to be evaluated in its MDSC assays. TuHURA expects to select a lead DOR inhibitor to conjugate to TBS-2025 for testing in preclinical models; (ii) Q3 2026: Anticipates first proof of concept in-vivo results from its lead immune modulating ADC."

Pipeline update • Preclinical • Oncology

Upcoming Targeted Milestones by Program:…APC and ADC Development Candidates (GlobeNewswire) - "TuHURA continues to advance its bi-specific, bi-functional immune modulating ADCs and APCs that target the Delta Opioid Receptor (DOR) on MDSCs....In 2025, TuHURA anticipates presenting non-clinical data at relevant medical meetings."

Preclinical • Oncology

TuHURA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update (PRNewswire) - "Upcoming Anticipated Milestones by Program:...ADC and APC Development Candidates: TuHURA continues to advance its bi-specific, bi-functional immune modulating ADCs and APCs that target the DOR on MDSCs, inhibiting their immune suppressing effects in the tumor microenvironment while localizing a checkpoint inhibitor like the VISTA inhibiting antibody. In 2025, TuHURA anticipates presenting non-clinical data at relevant medical meetings."

Preclinical • Oncology